Renaissance of the biologically active vitamin A derivatives: Established and novel directed therapies for cancer and chemoprevention

Current Pharmaceutical Design

Volumn 9, Issue 25, 2003, Pages 2067-2077

  Brtko, Julius ^a   Thalhamer, J ^b  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^b UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Apoptosis; Cancer chemoprevention; Cancer therapy; Nuclear retinoid acid receptors; Regulation of transcription; Retinoid inducible transcription factors; Retinoids; Rexinoids

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ACETYLCYSTEINE; ALITRETINOIN; ALPHA2A INTERFERON; ANTIESTROGEN; BETA CAROTENE; BEXAROTENE; CELL NUCLEUS RECEPTOR; DNA; FENRETINIDE; ISOTRETINOIN; LEVOTHYROXINE; LIGAND; POLYPRENOIC ACID; RADIOACTIVE IODINE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOL ACETATE; RETINOL DERIVATIVE; RETINOL PALMITATE; TAMIBAROTENE; TAMOXIFEN; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASANOID;

BLADDER CANCER; BLADDER SURGERY; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; DIGESTIVE SYSTEM CANCER; DNA BINDING; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NONHUMAN; OVARY CANCER; PRECANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; TERATOGENICITY; THYROID CANCER; THYROID SURGERY; TISSUE DIFFERENTIATION; TISSUE INJURY; TRANSCRIPTION REGULATION;

ANTICARCINOGENIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; RETINOIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0141761369     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454144     Document Type: Review

References (157)

1. DeLuca LM. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J 1991; 5: 2924-33.
2. Lotan R. Retinoids and apoptosis: Implication for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87: 1655-7.
3. Sun S-Y, Lotan R. Retinoids as chemopreventive and therapeutic agents. Drugs Fut 1998; 23: 621-34.
4. Allen JG, Bloxham DP. The pharmacology and pharmacokinetics of the retinoids. Pharmac Ther 1989; 40: 1-27.
5. Hinds TS, West WL, Knight EM. Carotenoids and retinoids: a review of research, clinical, and public health application. J Clin Pharmacol 1997; 37: 551-8.
6. Nagpal S, Friant S, Nakshatri H, Chambon P. RARs and RXRs: Evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J 1993; 12: 2349-60.
7. Mader S, Leroy P, Chen JY, Chambon P. Multiple parameters control the selectivity of nuclear receptors for their response elements. J Biol Chem 1993; 268: 591-600.
8. Durand B, Saunders M, Gaudon C, Roy B, Losson R, Chambon P. Activation function (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutively activating domain and influence of the nature of the response element. EMBO J 1994; 13: 5370-82.
9. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-9.
10. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-5.
11. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81: 1269-1304.
12. Minucci S, Leid M, Toyama R, Saint-Jeannet JP, Peterson VJ, Horn V, et al. Retinoid X receptor (RXR) within the RXR-retinoic acid receptor heterodimer binds its ligand and enhances retinoid dependent gene expression. Mol Cell Biol 1997; 17: 644-55.
13. Crowe DL. Receptor selective synthetic retinoids as potential cancer chemotherapy agents. Curr Cancer Drug Targets 2002; 2: 77-86.
14. Sun S-Y, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002; 41: 41-55.
15. Freedman, LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999; 97: 5-8.
16. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
17. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
18. Willy PJ, Mangelsdorf DJ. Nuclear orphan receptors: the search for novel ligands and signaling pathways. Horm Signal 1998; 1: 307-58.
19. Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W, et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J 1999; 18: 7011-8.
20. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525-30.
21. Szabova L, Macejova D, Dvorcakova M, Mostbock S, Blazickova S, Zorad S, et al. Expression of nuclear retinoic acid receptor in peripheral mononuclear cells (PBMC) of healthy subjects. Life Sci 2003; 72: 831-6.
22. Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS. Editors. The retinoids. New York: Raven Press; 1994. p. 319-50.
23. de The H. Altered retinoic acid receptors. FASEB J 1996; 10: 955-60.
24. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet 1999; 15: 179-84.
25. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-89.
26. Chen Z, Brand NJ, Chen A, Chen SJ, Tong JH, Wang ZY, et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor α locus due to a variant t(11; 17) translocation associated with acute promyelocytic leukemia. EMBO J 1993; 12: 1161-7.
27. Zhang J-W, Gu J, Wang Z-Y, Chen S-J, Chen Z. Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. J Biosci 2000; 25: 275-84.
28. Melnick A, Licht JD. Deconstructing a disease: RAR alpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-215.
29. He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 1999; 18: 5278-92.
30. Chen Z, Tong JH, Dong S, Zhu J, Wang ZY, Chen SJ. Retinoic acid regulatory pathways, chromosomal translocations and acute promyelocytic leukemia. Genes Chromosomes Cancer 1996; 15: 147-56.
31. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, et al. The PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88: 2826-32.
32. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, et al. Accelerated degradation of PML-retinoic acid receptor a (PML-RARA) oncoprotein by all-trans retinoic acid in acute promyelocytic leukemia. Cancer Res 1996; 56: 2945-8.
33. Marth C, Bock G, Daxenbichler G. Effect of 4-hydroxyphenylretinamide and retinoic acid on proliferation and cell cycle of cultured human breast cancer cells. J Natl Cancer Inst 1985; 75: 871-5.
34. Fontana JA, Mezu AB, Copper BN, Miranda D. Retinoid modulation of estradiol-stimulated growth and of protein synthesis and secretion in human breast carcinoma cells. Cancer Res 1990; 50: 1997-2002.
35. Macejova D, Dvorcakova M, Weiss R, Scheiblhofer S, Mostbock S, Liska J, et al. Reduction of 1-methyl-1-nitrosourea-insuced mammary gland carcinoma by in vivo application of immunostimulatory CpG motifs in Sprague-Dawley rats. Gen Physiol Biophys 2001; 20: 445-8.
36. Mehta RG. Experimental basis for the prevention of breast cancer. Eur J Cancer 2000; 36: 1275-82.
37. Liska J, Galbavy S, Macejova D, Zlatos J, Brtko J. Histopathology of mammary tumors in female rats treated with 1-methyl-1-nitrosourea. Endocr Regul 2000; 34: 91-6.
38. Liska J, Galbavy S, Zlatos J, Macejova D, Micincova M, Brtko J. Mammary tumors in female rats developed after 1-methyl-1nitrosourea treatment. Biologia 2000; 55: 63-7.
39. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56: 5566-70.
40. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Moshin SK, Xu XC, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev 2002; 11: 467-74.
41. Moon RC, Constantinou AI. Dietary retinoids and carotenoids in rodent models of mammary tumorigenesis. Breast Cancer Res Treat 1997; 46: 181-9.
42. Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, et al. Novel therapeuric approach: ligands for PPAR gamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat 2002; 74: 155-65.
43. Zhang X-K, Yi L, Lee M-O. Retinoid receptors in human lung and breast cancer. Mutat Res 1996; 350: 267-77.
44. Zujewski J, Pai L, Wakefield L, Giusti R, Dorr FA, Flanders C, et al. Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat 1999; 57: 277-83.
45. Fraker LC, Halter SA, Forbes JT. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res 1984; 44: 5757-63.
46. Singletary E, Lieberman R, Atkinson N, Sneige N, Sahin A, Tolley S, et al. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. Cancer Epidemiol Biomarkers Prev 2000; 9: 1087-90.
47. Van der Leede BJ, Folkers GE, van den Brink CE, van der Saag PT, van der Burg B. Retinoic acid receptor α1 isoform is induced by estradiol and confers retinoic acid sensitivity in human breast cancer cells. Mol Cell Endocrinol 1995; 109: 77-86.
48. Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res 2001; 3: 99-103.
49. Moon RC, Mehta RG. Chemoprevention of mammary cancer by retinoids. Basic Life Sci 1990; 52: 213-24.
50. Costa A. Breast cancer chemoprevention. Eur J Cancer 1993; 29A: 589-92.
51. Sporn MB. Retinoids and demethylating agents - looking for partners. J Natl Cancer Inst 2000; 92: 780-1.
52. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J Natl Cancer Inst 2000; 92: 826-32.
53. Lin B, Chen C-Q, Xiao D, Kolluri SK, Cao X, Su H, et al. Orphan receptor COUP-TF is required for RAR beta induction, growth inhibition and apoptosis by retinoic acid in cancer cells. Mol Cell Biol 2000; 20: 957-70.
54. Zhang X-K. Vitamin A and apoptosis in prostate cancer. Endo Related Cancer 2002; 9: 87-102.
55. Melino G, Annicchiarico-Petruzzelli M, Piredda L, Candi E, Gentile V, Davies PJ, et al. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994; 14: 6584-96.
56. Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. Expression of retinoic acid beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ 1995; 6: 1077-88.
57. Krupitza G, Hulla W, Harant H, Dittrich E, Kallay E, Huber H, et al. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation. Int J Cancer 1995; 61: 649-57.
58. Oridate N, Lotan D, Mitchell MF, Hong WK, Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implication of chemoprevention. J Cell Biochem Suppl 1995; 23: 80-6.
59. Nagy L, Thomazy VA, Heyman RA, Davies PJA. Retinoid-induced apoptosis in normal and neoplasic tissues. Cell Death Differ 1998; 5: 11-9.
60. Lin M, Iawarone A, Freedman L. Retinoid induction of U937 cell differentiation: transcriptional activation of the human p21WAFI/CIP1 gene by retinoic acid receptor. J Biol Chem 1996; 271: 31723-8.
61. Boccia M, Xu Q, Wesley U, Xu Y, Korontsvit T, Loganzo F, et al. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. Leuk Res 1997; 21: 439-47.
62. Nagy L, Thomazy VA, Heyman RA, Chandraratna RAS, Davies PJA. Retinoid-regulated expression of BCL-2 and tissue transglutaminase during differentiation and apoptosis of human myeloid leukemia (HL-60) cells. Leuk Res 1996; 19: 499-505.
63. Chiocca EA, Davies PJ, Stein JP. The molecular basis of retinoic acid action. Transcriptional regulation of tissue transglutaminase gene expression in macrophages. J Biol Chem 1988; 263: 11584-9.
64. Riboni L, Pribetti A, Bassi R, Caminiti A, Tettamanti G. A mediator role of ceramide in the regulation of neuroblastoma Neuro2a cell differentiation. J Biol Chem 1995; 270: 26868-75.
65. Mostbock S, Macejova D, Baranova M, Weiss R, Scheiblhofer S, Verwanger T, et al. Analysis of altered gene expression profiles in retinoic acid or CpG treated Sprague-Dawley rats with MNU-induced mammary adenocarcinoma by cDNA macro array. Gen Physiol Biophys 2003; (In press).
66. Gebert JF, Moghal N, Frangioni JV, Sugarbaker DJ, Neel BG. High frequency of retinoic acid receptor β abnormalities in human lung cancer. Oncogene 1991; 6: 1859-68.
67. Lotan R. Retinoids and chemoprevention of aerodigestive tract cancers. Cancer Metastasis Rev 1997; 16: 349-56.
68. The Alpha Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
69. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
70. Van Zandwijk N. Chemoprevention of lung cancer. Lung Cancer 2001; 34: S91-S94.
71. Arora A, Willhite CA, Liebler DC. Interactions of beta-carotene and cigarette smoke in human bronchial epithelial cells. Carcinogenesis 2001; 22: 1173-8.
72. Van Zandwijk N, Dalesio O, Pastorino U, DeVries N, Van Tinteren H. EUROSCAN, a randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients with head and neck or lung cancer. J Natl Cancer Inst 2000; 92: 977-86.
73. Toma S, Raffo P, Isnardi L, Palumbo R. Retinoids in lung cancer chemoprevention and treatment. Ann Oncol 1999; 10: Suppl 5, S95-S102.
74. Van Herle AJ, Agatep ML, Padua DN 3rd, Van Herle HML, Juillard, GJF. Effects of 13-cis retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA RO 82 W-1) in vitro. J Clin Endocrinol Metab 1990; 71: 755-63.
75. Schreck R, Schneiders F, Schmutzler C, Kohrle J. Retinoids stimulate type-I iodothyronine 5′-deiodinase activity in human follicular thyroid - carcinoma cell lines. J Clin Endocrinol Metab 1994; 79: 791-8.
76. Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997; 240: 832-8.
77. Schmutzler C, Schmitt TL, Glaser F, Loos U, Kohrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 2002; 189: 145-55.
78. Bassi V, Vitale M, Feliciello A, De Riu S, Rossi G, Fenzi G. Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines. J Clin Endocrinol Metab 1995; 80: 1129-35.
79. Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, Aust G, et al. Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 1104-9.
80. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000; 10: 393-406.
81. Van Sande J, Parma J, Tonacchera M, Swillens S, Dumont J, Vassart, G. Genetic basis of endocrine disease: somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 1995; 80: 2577-85.
82. Brtko J, Bobalova J, Podoba J, Schmutzler C, Kohrle, J. Thyroid hormone receptors and type I iodothyronine 5′-deiodinase activity of human thyroid toxic adenomas and benign cold nodules. Exp Clin Endocrinol Diabetes 2002; 110: 166-70.
83. Rochefort P, Caillou B, Michiels F-M, Ledent C, Talbot M, Schlumberger M, et al. Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Oncogene 1096; 12: 111-8.
84. Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corstens FH. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 2000; 41: 643-6.
85. Schmutzler C, Koehrle J. Innovative strategies for treatment of thyroid cancer. Eur. J. Endocrinol. 2000; 143: 15-24.
86. Schmutzler C, Brtko J, Bienert K, Kohrle J. Effect of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabetes 1996; 104: (Suppl. 4), 16-9.
87. Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D, et al. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 1998; 76: 368-76.
88. Brtko J. Accurate determination and physicochemical properties of rat liver nuclear retinoic acid (RA) receptors. Biochem Biophys Res Commun 1994; 204: 439-45.
89. Brtko J, Hartl A, Weiss R, Bernhaupt A, Scheiblhofer S, Mostbock S, et al. DNA immunization in vivo down-regulates nuclear all-trans retinoic acid receptors in mouse spleen cells. Mol Cell Endocrinol 2000; 165: 107-13.
90. Brtko J, Hartl A, Weiss R, Scheiblhofer S, Mostboeck S, Thalhamer J. Retinoic acid receptor status in mouse spleen during a primary immune response against beta-galactosidase. Endocr Regul 2000; 34: 113-8.
91. Simon D, Kohrle J, Reiners C, Boerner A, Schmutzler C, Mainz K, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22: 569-74.
92. Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, et al. Redifferentiation therapy - induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39: 1903-6.
93. 18F-FDG PET. Eur J Nucl Med 2002; 29: 231-6.
94. Hammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RA. The prospects of retinoids in the treatment of prostate cancer. Anticancer Drugs 2002; 13: 781-90.
95. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-Dihydroxyvitamin D3 and 9-cis retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997; 138: 1491-7.
96. McCormick DL, Rao KV, Steele VE, Lubet RA, Kelloff GJ, Bosland MC. Chemoprevention of rat prostate carcinogenesis by 9-cis retinoic acid. Cancer Res 1999; 59: 521-4.
97. Kelly WK, Osman I, Reuter VE, Curley T, Heston WD, Nanus DM, et al. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res 2000; 6: 838-46.
98. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 2001; 61: 1477-85.
99. Pasquali D, Rossi V, Prezioso D, Gentile V, Colantuoni V, Lotti T, et al. Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. J Clin Endocrinol Metab 1999; 84: 1463-9.
100. Koshiuka K, Elstner E, Williamson E, Said JW, Tada Y, Koeffler HP. Novel therapeutic approach: organic arsenical melarsoprol alone or with all-trans retinoic acid markedly inhibits growth of human breast and prostate cancer cells in vitro and in vivo. Br J Cancer 2000; 82: 452-8.
101. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403-10.
102. Webber MM, Bello-DeOcampo D, Quader S, DeOcampo ND, Metcalfe WS, Sharp RM. Modulation of the malignant phenotype of human prostate cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin Exp Metastasis 1999; 17: 255-63.
103. Bernard BA, Bernardon JM, Delescluse C, Martin B, Lenoir MC, Maignan J, et al. Identification of synthetic retinoids with selectivity for human retinoic acid receptor gamma. Biochem Biophys Res Commun 1992; 186: 977-83.
104. Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. Retinoids and ovarian cancer. J Cell Physiol 2000; 185: 1-20.
105. Langdon SP, Rabiasz GJ, Ritchie AA, Reichert U, Buchan P, Miller WR, et al. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother Pharmacol 1998; 42: 429-32.
106. Formelli F, Cleris L. Synthetic retinoid fenretidine is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 1993; 53: 5374-6.
107. DePalo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, et al. Can fenretidine protect women against ovarian cancer? J Natl Cancer Inst 1995; 87: 146-7.
108. Spencer CC. Effects of retinoids on ovarian cancer cells. Obstet Gynecol 2000; 95: (Suppl. 1) S5.
109. Berg WJ, Nanus DM, Leung A, Brown KT, Hutchinson B, Mazumdar M, et al. Up-regulation of retinoic acid receptor β expression in renal cancers in vivo correlates with response to 13-cis retinoic acid and interferon-α-2a. Clin Cancer Res 1999; 5: 1671-5.
110. Pantuck A, Zisman A, Belldegrun A. Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. Rev Urol 2000; 2: 22-4.
111. Nutting C, Huddart RA. Rethinking the secondary prevention of superficial bladder cancer: is there a role for retinoids ? BJU International 2000; 85: 1023-6.
112. Mathews-Roth MM, Lausen N, Drouin A, Krinsky NI. Effects of carotenoid administration on bladder cancer prevention. Oncology 1991; 48: 177-9.
113. Moon RC, Detrisac CJ, Thomas CF, Kelloff GJ. Chemoprevention of experimental bladder cancer. J Cell Biochem 1992; 161: 134-8.
114. Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer. Lancet 1998; 351: 214-5.
115. Blomhoff R, Wake K. Perisinusoidal stellate cells of the liver: important roles in retinal metabolism and fibrosis. FASEB J 1991; 5: 271-7.
116. Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, et al. Retinoids in liver fibrosis and cancer. Front Biosci 2002; 7: 204-18.
117. Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995; 207: 382-8.
118. Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, et al. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology 2002; 36: 1115-24.
119. Riecken EO, Rosewicz S. Retinoids in pancreatic cancer. Ann Oncol 1999; 10: Suppl. 4, 197-200.
120. Niles RM. The use of retinoids in the prevention and treatment of skin cancer. Expert Opin Pharmacother 2002; 3: 299-303.
121. Zusi FC, Lorenzi MV, Vivat-Hannah V. Selective retinoids and rexinoids in cancer therapy and chemoprevention. DDT 2002; 7: 1165-74.
122. Kagechika H, Kawachi E, Hashimoto Y, Himi T, Shudo K. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J Med Chem 1988; 31: 2182-92.
123. Teng M, Duong TT, Klein ES, Pino ME, Chandraratna RA. Identification of a retinoic acid receptor alpha subtype specific agonist. J Med Chem 1996; 39: 3035-8.
124. Kikuchi K, Hibi S, Yoshimura H, Tokuhara N, Tai K, Hida T, et al. Syntheses and structure-activity relationship of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxa-line derivatives with retinoic acid receptor alpha agonistic activity. J Med Chem 2000; 43: 409-19.
125. Chen JY, Penco S, Ostrowski J, Balaguer P, Pons M, Starrett JE, et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J 1995; 14: 1187-97.
126. Johnson AT, Klein ES, Wang L, Pino ME, Chandraratna RA. Identification of retinoic acid receptor beta subtype specific agonists. J Med Chem 1996; 39: 5027-30.
127. Klaholz BP, Mitschler A, Belema M, Zusi C, Moras D. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRAR gamma. Proc Natl Acad Sci USA 2000; 97: 6322-7.
128. Meunier L, Bohjanen K, Voorhees JJ, Cooper KD. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation. J Invest Dermatol 1994; 103: 775-9.
129. Szabo G, Puppolo M, Verma B, Catalano D. Regulatory potential of ethanol and retinoic acid on human monocyte functions. Alcohol Clin Exp Res 1994; 18: 548-54.
130. Pohl J, LaFace D, Sands JF. Transcription of retinoic acid receptor genes in transgenic mice increases CD8 T-cell subset. Mol Biol Rep 1993; 17: 135-42.
131. Friedman A, Halevy O, Schrift M, Arazi Y, Sklan D. Retinoic acid promotes proliferation and induces expression of retinoic acid receptor-alpha gene in murine T lymphocytes. Cell Immunol 1993; 152: 240-8.
132. Lomo J, Smeland EB, Ulven S, Natarajan V, Blomhoff R, Gandhi U, et al. RAR-, not RXR, ligands inhibit cell activation and prevent apoptosis in B-lymphocytes. J Cell Physiol 1998; 175: 68-77.
133. Hoag KA, Nashold FE, Goverman J, Hayes CE. Retinoic acid enhances the T helper 2 cell development that is essential for robust antibody responses through its action on antigen-presenting cells. J Nutr 2002; 132: 3736-9.
134. Aoudjit F, Bosse M, Stratowa C, Voraberger G, Audette M. Regulation of intercellular adhesion molecule-1 expression by retinoic acid: analysis of the 5′ regulatory region of the gene. Int J Cancer 1994; 58: 543-9.
135. Aoudjit F, Brochu N, Morin N, Poulin G, Stratowa C, Audette M. Heterodimeric retinoic acid receptor-beta and retinoid X receptor-alpha complexes stimulate expression of the intercellular adhesion molecule-1 gene. Cell Growth Differ 1995; 6: 515-21.
136. Babina M, Mammeri K, Henz BM. Retinoic acid up-regulates myeloid ICAM-3 expression and function in a cell-specific fashion-evidence for retinoid signaling pathways in the mast cell lineage. J Leukoc Biol 2001; 69: 361-72.
137. Ballow M, Xiang S, Greenberg SJ, Brodsky L, Allen C, Rich G. Retinoic acid-induced modulation of IL-2 mRNA production and IL-2 receptor expression on T cells. Int Arch Allergy Immunol 1997; 113: 167-9.
138. de Grazia U, Felli MP, Vacca A, Farina AR, Maroder M, Cappabianca L, et al. Positive and negative regulation of the composite octamer motif of the interleukin 2 enhancer by AP-1, Oct-2, and retinoic acid receptor. J Exp Med 1994; 180: 1485-97.
139. Ertesvag A, Engedal N, Naderi S, Blomhoff HK. Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J Immunol 2002; 169: 5555-63.
140. Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 1995; 154: 450-8.
141. Cippitelli M, Ye J, Viggiano V, Sica A, Ghosh P, Gulino A, et al. Retinoic acid-induced transcriptional modulation of the human interferon-gamma promoter. J Biol Chem 1996; 271: 26783-93.
142. Baj G, Arnulfo A, Deaglio S, Tibaldi E, Surico N, Malavasi F. All-trans retinoic acid inhibits the growth of breast cancer cells by up-regulating ICAM-1 expression. J Biol Regul Homeost Agents 1999; 13: 115-22.
143. Szondy Z, Lecoeur H, Fesus L, Gougeon ML. All-trans retinoic acid inhibition of anti-CD3-induced T cell apoptosis in human immunodeficiency virus infection mostly concerns CD4 T lymphocytes and is mediated via regulation of CD95 ligand expression. J Infect Dis 1998; 178: 1288-98.
144. Yang Y, Minucci S, Zand DJ, Ozato K, Ashwell JD. T cell activation and increases in protein kinase C activity enhance retinoic acid-induced gene transcription. Mol Endocrinol 1994; 8: 1370-6.
145. Worm M, Krah JM, Manz RA, Henz BM. Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood 1998; 92: 1713-20.
146. Naderi S, Blomhoff HK. Retinoic acid prevents phosphorylation of pRB in normal human B lymphocytes: regulation of cyclin E, cyclin A, and p21(Cip1). Blood 1999; 94: 1348-58.
147. Ricciardi-Castagnoli P, Granucci F. Opinion: Interpretation of the complexity of innate immune responses by functional genomics. Nat Rev Immunol 2002; 2: 881-9.
148. Granucci F, Castagnoli PR, Rogge L, Sinigaglia F. Gene expression profiling in immune cells using microarray. Int Arch Allergy Immunol 2001; 126: 257-66.
149. Richards J, Le Naour F, Hanash S, Beretta L. Integrated genomic and proteomic analysis of signaling pathways in dendritic cell differentiation and maturation. Ann NY Acad Sci 2002; 975: 91-100.
150. Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, et al. Signatures of the immune response. Immunity 2001; 15: 375-85.
151. Li A, Zhu X, Brown B, Craft CM. Gene expression networks underlying retinoic acid-induced differentiation of human retinoblastoma cells. Invest Ophthalmol Vis Sci 2003; 44: 996-1007.
152. Witcher M, Ross DT, Rousseau C, Deluca L, Miller WH. Synergy between all trans retinoic acid and tumor necrosis factor pathways in acute leukemia cells. Blood 2003; 13: (in press).
153. Ishida S, Shigemoto-Mogami Y, Kagechika H, Shudo K, Ozawa S, Sawada J, et al. Clinically potential subclasses of retinoid synergists revealed by gene expression profiling. Mol Cancer Ther 2003; 2: 49-58.
154. Lee KH, Chang MY, Ahn JI, Yu DH, Jung SS, Choi JH, et al. Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells. Biochem Biophys Res Commun 2002; 296: 1125-33.
155. Frank S, Ebert AD. License to kill tumors: how much hope is justified for trail? Curr Pharm Des 2001; 7(16): 1689-701.
156. Simoni D, Tolomeo M. Retinoids apoptosis and cancer. Curr Pharm Des 2001; 7(17): 1823-37.
157. Tzimas G, Nau H. The role of metabolism and toxicokinetics in retinoid teratogenesis. Curr Pharm Des 2001; 7(9): 803-31.